---
title: "Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citic Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289404166.md"
description: "Citic Securities analyst maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H on June 9 and set a price target of HK$119.00.Introducing TipRanks MCP for Agents Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools. Designed for personal research, portfolio monitoring, and AI-assisted investment workflows. Currently, the analyst consensus on Shanghai Henlius Biotech, Inc. Class H is a Strong Buy with an average price target of HK$99.12."
datetime: "2026-06-11T02:45:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289404166.md)
  - [en](https://longbridge.com/en/news/289404166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289404166.md)
---

# Shanghai Henlius Biotech, Inc. Class H (2696) Gets a Buy from Citic Securities

Citic Securities analyst maintained a Buy rating on Shanghai Henlius Biotech, Inc. Class H on June 9 and set a price target of HK$119.00.

### Introducing TipRanks MCP for Agents

-   Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
-   Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Currently, the analyst consensus on Shanghai Henlius Biotech, Inc. Class H is a Strong Buy with an average price target of HK$99.12.

### Related Stocks

- [02696.HK](https://longbridge.com/en/quote/02696.HK.md)
- [06030.HK](https://longbridge.com/en/quote/06030.HK.md)
- [600030.CN](https://longbridge.com/en/quote/600030.CN.md)

## Related News & Research

- [Henlius unit Shanghai Henlius Biologics passes China GMP inspection for HANBEIYOU production lines](https://longbridge.com/en/news/290027006.md)
- [Biotech Breaks Out As Pharma Starts Looking Past 2031](https://longbridge.com/en/news/290679359.md)
- [Henlius Grants New Share Options and RSUs to Align Incentives With Performance](https://longbridge.com/en/news/283152010.md)
- [Alligator Bioscience Comments on Henlius Update on Global Phase 3 Trial with HLX22](https://longbridge.com/en/news/289014793.md)
- [Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N](https://longbridge.com/en/news/285838804.md)